Latest News

Johnson & Johnson Rolls Out Data From Major Depressive Disorder Portfolio at ECNP / image credit ©KieferPix/Shutterstock.com
Johnson & Johnson Rolls Out Data From Major Depressive Disorder Portfolio at ECNP

October 10th 2025

Clinical and real-world data are on deck for lumateperone, seltorexant, and esketamine to treat major depressive disorder and treatment-resistant depression.

Precision Medicine Protocol for Cognitive Decline Also Reduces Depression, New Data Suggest image credit ©Maxim/stock.adobe.com
Precision Medicine Protocol for Cognitive Decline Also Reduces Depression, New Data Suggest

October 3rd 2025

Lipocene Updates Progress on Phase 3 Clinical Trial in Postpartum Depression with LPCN 1154 / image courtesy of Lipocene
Lipocine Updates Progress on Phase 3 Clinical Trial in Postpartum Depression with LPCN 1154

October 1st 2025

NeuroStim Announces Single-Day TMS Protocol With High Remission Rates in Depression / image credit ©PATTARAWIT/stock.adobe.com
NeuroStim Announces Single-Day TMS Protocol With High Remission Rates in Depression

August 26th 2025

Risk of Major Depressive Disorder Spikes Following a Medical Diagnosis, Endures for Decades  / image credit ©Justlight/stock.adobe.com
Risk of Major Depressive Disorder Spikes Following a Medical Diagnosis, Endures for Decades: New Data

August 20th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.